A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients with Solid Tumors

Inclusion Criteria:

• Patients with unresectable or metastatic solid tumors willing to provide signedinformed consent.

• Histopathological diagnosis and metastatic status cancer at study entry.

• Must have received at least 1 prior line of systemic therapy for metastatic diseasebut no more than 3 prior lines of treatment for metastatic disease.

• Life expectancy of more than 6 months.

• Eastern Cooperative Oncology Group (ECOG) performance status (PS) score or less than

• Adequate organ and hematological function.

• Measurable disease by RECIST v1.1 and iRECIST.

Exclusion Criteria:

• Patient has known untreated or symptomatic central nervous system metastasis.

• Patient is receiving systemic glucocorticoids or other immunosuppressive treatmentsfor autoimmune disease or any other medical condition.

• Patient has experienced a severe hypersensitivity reaction to another monoclonalantibody.

• Patient has received treatment with any systemic anti-cancer therapies within 3weeks prior to starting study treatment.

• Patient has undergone radiotherapy ≤ 4 weeks prior to starting study treatment.

• Patient has received > 3 lines of prior systemic chemotherapy for metastatic disease